Jia‐Cheng Lu
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 5%
- Circular RNAs in diseases
- Extracellular vesicles in disease
- RNA modifications and cancer
- CRISPR and Genetic Engineering
Papers in
-
- Cancer, Hypoxia, and Metabolism 5
- Oncology 14
- Peptidase Inhibition and Analysis 5
- Co-authors
- Ai‐Wu KePengfei ZhangChao GaoXiaoyong HuangJiabin CaiGuo‐Ming ShiXiaojun GuoJia Fan
- Journals
- Molecular Cancer (4 papers)Cell Death and Disease (3 papers)Journal of Clinical Oncology (3 papers)Frontiers in Immunology (2 papers)Journal of Cardiovascular Translational Research (2 papers)
- Partner nations
- ChinaUnited StatesEthiopia
In The Last Decade
Jia‐Cheng Lu
33 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Cancer Research 988
- Molecular Biology 1.5k
- Oncology 436
- Immunology 294
- Business and International Management 17
Countries citing papers authored by Jia‐Cheng Lu
This map shows the geographic impact of Jia‐Cheng Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jia‐Cheng Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jia‐Cheng Lu more than expected).
Fields of papers citing papers by Jia‐Cheng Lu
This network shows the impact of papers produced by Jia‐Cheng Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jia‐Cheng Lu. The network helps show where Jia‐Cheng Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jia‐Cheng Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2023 | 8 | |
| 4 | 2023 | 14 | |
| 5 | Current applications and future perspective of CRISPR/Cas9 gene editing in cancer Hit paper breakdown → | 2022 | 292 |
| 6 | 2022 | 23 | |
| 7 | 2022 | 4 | |
| 8 | 2021 | 26 | |
| 9 | 2020 | 178 | |
| 10 | Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma Hit paper breakdown → | 2020 | 465 |
| 11 | 2020 | 12 | |
| 12 | 2019 | 39 | |
| 13 | 2019 | 45 | |
| 14 | 2019 | 42 | |
| 15 | 2019 | 174 | |
| 16 | 2019 | 122 | |
| 17 | 2019 | 75 | |
| 18 | 2018 | 40 | |
| 19 | 2017 | 38 | |
| 20 | 2016 | 31 |
About Jia‐Cheng Lu
Jia‐Cheng Lu is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Molecular Biology, having authored 35 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Cancer Mechanisms and Therapy (6 papers), Ubiquitin and proteasome pathways (6 papers), Cancer, Hypoxia, and Metabolism (5 papers), RNA modifications and cancer (5 papers), Peptidase Inhibition and Analysis (5 papers), Circular RNAs in diseases (5 papers) and Glioma Diagnosis and Treatment (4 papers). The work is most often cited by research in Cancer Research (988 citations), Molecular Biology (1.5k citations), Oncology (436 citations), Immunology (294 citations) and Business and International Management (17 citations). Jia‐Cheng Lu has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Ai‐Wu Ke, Pengfei Zhang, Chao Gao, Xiaoyong Huang, Jiabin Cai, Guo‐Ming Shi, Xiaojun Guo, Jia Fan, Chuanyuan Wei and Xuan Yang. Their work appears in journals such as Molecular Cancer, Cell Death and Disease, Journal of Clinical Oncology, Frontiers in Immunology and Journal of Cardiovascular Translational Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.